Takeover of terraplasma medical by the Viromed

New medical products from Max Planck research

December 09, 2021

The majority takeover of terraplasma medical by Viromed Plasma, a company of the Viromed Group, was announced today. Terraplasma, a spin-off of the Max Planck Institute for Extraterrestrial Physics, will continue to be involved in terraplasma medical as a partner in order to continue contributing its expertise in the field of cold atmospheric plasmas in the future. With plasma care® terraplasma medical has developed a mobile medical product and launched it on the market, which can treat chronic and acute wounds with its plasma technology, which is based on research results of the Max Planck Institute.

The aim of Viromed and terraplasma is to jointly build the world's leading company and innovation leader for medical products with cold atmospheric plasma in a wide variety of medical fields of application.

Cold atmospheric plasma inactivates bacteria, multi-resistant pathogens, viruses and also fungi in a highly effective physical-chemical way. Its use in medical technology can revolutionize, supplement and, in some cases, replace conventional treatment methods, for example in surgery for postoperative wounds to avoid infections. In nursing, cold atmospheric plasma offers a therapy option for chronic, often long-term and non-healing wounds. Cold plasma treatment reduces the use of antibiotics or cortisone and does not cause allergic side effects or pain. The plasma care® product line developed by terraplasma medical for this purpose, which uses cold atmospheric plasma in medical technology, is to be expanded further in the future.

Reduced use of antibiotics and anti-inflammatory drugs

Clinical experience over the last few years has shown that this new form of therapy, in addition to its bactericidal and healing properties, offers additional benefits for the healthcare system: e.g. a reduction in care and wound dressing costs or, in postoperative use, the avoidance of complications and longer hospital stays. By reducing the use of antibiotics, the resulting resistances can be avoided and less anti-inflammatory drugs can be used in dermatology. Ultimately, successful therapy for diabetic feet or open legs, for example, significantly improves the quality of life of the patient.

With the entry of Viromed, the already existing, very successful cooperation is to be significantly intensified and expanded. This applies in particular to the broad marketing of the plasma care® product range, says Uwe Perbandt. The Perbandt family is the owner of the Viromed Group through its holding company, Perbamed Invest GmbH.

Jens Kirsch, CEO of terraplasma medical GmbH, is pleased to have won an extremely strong sales and financially strong partner in the Viromed Group. Julia Zimmermann, CEO of terraplasma GmbH, a spin-off of the Max Planck Society, is enthusiastic about developing innovative medical products for various medical applications together with terraplasma medical and establishing them successfully in the market. "The departing shareholders of the investor group around Kuenheim Familiaris are proud to have accompanied such a successful company development," says Fabian von Kuenheim.

Max Planck Innovation, the central technology transfer organization of the Max Planck Society, has accompanied terraplasma from the beginning in the context of advice, patenting of research results, licensing and as a shareholder representative. " Together with the Max Planck spin-off terraplasma we are pleased about the great success with the subsidiary of terraplasma medical, in which, among other things, findings from basic research on cold plasma at the Max Planck Institute for Extraterrestrial Physics have already been successfully applied to patients. We wish terraplasma and their new strong partner Viromed Plasma every success in developing and introducing new products from terraplasma medical for many other medical applications, ”says Ulrich Mahr, member of the management team at Max Planck Innovation.

Go to Editor View